EWTX
Servier to acquire Edgewises muscular dystrophy business for $2.65bn
Article Summary
HOLD- Edgewise Therapeutics (NYSE: EGTX) and Servier signed an agreement to acquire the company's muscular dystrophy business in a deal valued at up to $2.65bn, including a $1.55bn upfront payment and as much as $ 1.1bn in regulatory and commercial milestone payments.
- The acquisition aligns with Servier's strategic goal in rare neurology, addressing the medical needs of currently underserved patients, with Edgewise Therapeutics assuming control of assets including sevasemten, an orally administered fast skeletal myosin inhibitor currently under pivotal investigation in Becker muscular dystrophies and in Phase II development for Duchenne muscular dyastrophy.
- Both organisations' governance bodies have approved the transaction, which will proceed following required regulatory review and satisfaction of closing conditions, and the companies anticipate finalising the acquisition in the third quarter of 2026.
- The transaction's completion remains subject to regulatory clearance and customary conditions as both companies prepare for integration of the muscular Dystrophy portfolio.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | -0.2% | 25% | 0.0 ptsNegative (-0.2%) - Declining expectations |
| Target Price Upside ? | 16.1% | 20% | 60.0 ptsModerate Upside (16.1%) - Target: $45.17 vs Current: $38.92 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -4.5% | 15% | 20.0 ptsBarely a Dip (-4.5%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About EWTX
- Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
- Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
- The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction.
- In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
- The company was incorporated in 2017 and is headquartered in Boulder, Colorado.